Chicago’s First Ultrasound Treatment for Prostate Cancer In September, a University of Chicago Medicine surgical team, led by Arieh Shalhav, MD, professor of surgery and director of the Robotic Surgery Program, used the Ablatherm® Robotic HIFU device to perform the first high-intensity focused ultra- sound (HIFU) procedure in the city of Chicago for a patient with prostate cancer. During the procedure, HIFU directs high-frequency sound waves that heat up and burn off targeted prostate tissue where the small tumors are located. This has little effect on nearby tissue containing healthy cells and can be focused to treat only the area that contains the cancer. The process minimizes side effects such as impotence or incontinence that are associated with radical prostate surgery. “As surgeons, we strive to find effective treatment options that are less disruptive to the human body and life, and set the stage for better and gentler ways of curing disease,” Shalhav said. “Focal HIFU fills a significant void between active surveillance—a watch and wait approach, which can be stressful—and radical treatments like whole gland removal, radiation or ablation. It bridges this gap and allows patients to maintain their quality of life.” This clinical achievement comple- ments the Comprehensive Cancer Center’s strong research program in HIFU. Radiologist Aytekin Oto, MD, professor of radiology and surgery, is a pioneer in develop- ing HIFU techniques for prostate cancer treatment. Innovative clin- ical trials using HIFU led by Oto and Scott Eggener, MD, profes- sor of surgery and radiology, were made possible by the installa- tion of a new Philips Ingenia 3.0T Magnetic Resonance (MR) scan- ner in the University of Chicago MRI Research Center. This work has received philanthropic sup­ port from the Forefront Fund and the University of Chicago Cancer Research Foundation Women’s Board. Charlie Barriball was UChicago Medicine’s first HIFU patient. 13